Skip to main content
. 2024 Mar 12;14(3):e072300. doi: 10.1136/bmjopen-2023-072300

Figure 2.

Figure 2

Unadjusted time to drug discontinuation in b/tsDMARD-naïve patients, Swiss Clinical Quality Management registry, 2017–2020. These Kaplan-Meier curves represent the crude ‘survival’ of drug prescription, by treatment group. Death and loss to follow-up are censored. BARI, baricitinib; OMA, other modes of action bDMARDs; TNFi, tumour necrosis factor inhibitors. Log-rank BARI versus TNFi: p=0.003. Log-rank BARI versus OMA: p=0.15.